# Aptadir Therapeutics

> RNA therapeutics company developing demethylating medicines; raised a €40 million seed round.

## Why it is interesting

An unusually large biotech seed round with multi-institution science and clear primary-source disclosure.

## Profile

- **Latest funding:** Seed — €40M ($45M) (September 29, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $45M
- **Stage:** seed
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** 4BIO Capital, EXTEND

## Key facts

- Sep 29, 2026: €40M seed
- 4BIO Capital led the round

## Funding history

- Seed · €40M ($45M) · September 29, 2026
  Source: https://www.globenewswire.com/news-release/2026/09/29/3370373/0/en/aptadir-raises-a-40m-45m-seed-financing-to-advance-first-in-class-demethylating-medicines.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/aptadir-therapeutics